Skip to main content
. 2017 Mar 29;8(27):44976–44993. doi: 10.18632/oncotarget.16689

Figure 3.

Figure 3

Meta-analyses of 24 (A) and 36 (B) months survival rates between thalidomide combined with TACE versus TACE alone in patients with primary HCC.